Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CD133(+) Cells for Diabetic Critical Limb Ischemia
NCT02915796Phase 1Unknown
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of autologous CD133+ cells in critical limb ischemia (CLI) (3 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Restenosis rate at 12 months, Peak systolic velocity ratio at 12 months and 1 more. Status: unknown.
02
Drugs
autologous CD133+ cells
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT02915796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915796.